Transforming the Future of Medicine
Pioneering Biotechnology for Life-Saving Therapies
From innovation to impact: because every patient deserves a future.
Turning science into hope, one breakthrough at a time.
Technology License Agreement
A historic milestone: Technology License Agreement signed for Türkiye's first locally produced CAR-T therapy.
Mission and Vision
Our Mission
"Our mission is to cure once incurable diseases
– advancing biotechnology to defeat cancer and beyond.
"
TCT is deeply committed to making next-generation treatments accessible to Turkish citizens through technology adaptation, bridging the gap between global innovations and local healthcare needs.
Our Vision
To position Turkey at the forefront of medical innovation and as a global destination for advanced healthcare.
- Transform the healthcare landscape with next-gen treatments
- Make advanced therapies accessible and affordable
- Establish Turkey as a hub for biotechnology and medical excellence
Our Core Values
Technology Excellence
We continuously invest in cutting-edge technology and infrastructure.
Accessibility
Making advanced therapies accessible and affordable for all.
Innovation Leadership
Positioning Turkey as a leader in healthcare innovation.
Patient-Centric
Placing patients at the center of everything we do.
TCT's Core Services
"Innovative therapies, cutting-edge research, and technology-driven solutions – all under one roof."
Licensing
TCT enables access to advanced cell and gene therapies through strategic licensing agreements with global partners.
Learn moreFlexFactory Centers
TCT has established state-of-the-art manufacturing facilities using Cytiva's FlexFactory platform for cell therapy production.
Learn morePrecision Medicine
TCT develops personalized treatment solutions tailored to individual patient needs through innovative diagnostic approaches.
Learn moreBreakthrough Treatments
Revolutionizing cancer treatment with next generation CAR-T therapy and the groundbreaking AT101 platform
CAR-T Platform
CAR-T therapy is a type of cell therapy where genetically modified immune cells from the patient selectively attack cancer cells. From Phase II clinical trials, it boasted nearly 90% complete remission rate and has been called a miracle anticancer drug.
TCT's proprietary zCAR-T treatment is the next generation of CAR-T treatment whose modularity can allow it to be used against various cancer targets as well modulating the activity of CAR-T cells within the patient.
Explore CAR-T Platform
CAR-T treatment for CD19-expressing hematologic cancer
AT101
AT101 is an advanced CAR-T therapy targeting CD19-expressing hematologic cancers with enhanced efficacy. Developed using TCT's proprietary technology, AT101 represents the next generation of targeted cancer treatment.
AbClon utilized the NEST discovery platform to derive a unique humanized antibody that demonstrates stronger therapeutic effects compared to existing CAR-T treatments and represents a new hope for patients who do not respond to current treatments.
Enhanced Efficacy
Unique Targeting
Advantages of our CAR-T platform
ON/OFF function
Precise control over T-cell activation for optimal treatment management
Controllable immune response
Adjustable treatment intensity based on patient needs
Expansion of cancer targets
Versatile platform adaptable to various types of cancer
Strategic Partnerships
Stronger together
Leveraging global expertise through strategic partnerships, TCT brings world-class innovation and next-generation treatments to patients in Türkiye
AbClon
AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Their mission is to cure once incurable diseases such as cancer.
Platforms
CAR-T
NEST
AffiMab
Cytiva
TCT is strengthening Türkiye's biotechnology ecosystem by launching an advanced bioprocessing and manufacturing platform for cell and gene therapies in partnership with Cytiva.
Advanced Manufacturing Capabilities
FlexFactory™
Cell Therapy Manufacturing Platform
FastTrak™
Accelerated Technology Transfer
TCT is establishing Türkiye's first FlexFactory facility, creating a state-of-the-art biotech hub for cell and gene therapy manufacturing.
Latest News
Stay updated with the latest developments, partnerships, and innovations at TCT Health Technology.
Sağlık Bakanı müjdeyi verdi! Yerli CAR-T tedavisi kanser hastalarına umut olacak...
Kanserle mücadelede geliştirilen yeni teknolojiler, her geçen gün kanser hastalarına yeni bir umut olmaya devam ediyor. CAR-T hücre tedavisi de o yeni teknolojilerden biri. Türkiye de kanser tedavisinde devrim yaratan bu tedavi için Güney Kore ve İsveç ile iş birliğine girdi. Yerel üretim ve klinik denemelerle hastalar, 2026’dan itibaren bu yenilikçi tedaviye erişebilecek. Kanserle mücadelede yeni bir umut kaynağı olan bu teknolojiyi, uzmanlar Hurriyet.com.tr’ye anlattı.
AbClon signs technology transfer agreement for CAR-T cell therapy candidate 'AT101', terms unspecified
Final Agreement Reached with Türkiye's TCT Health Technology for AT101 Commercialization By Kang, In Hyo Korean biotech company AbClon has officially begun its full-scale entry into the global market with its CAR-T cell therapy candidate, AT101 (development code). On March 4, AbClon announced that it signed a final contract with local company TCT Health Technology for the commercialization of AT101 in Istanbul, Türkiye, on the afternoon of February 28 (local time). Through this agreement, AbClon aims to enter the Turkish blood cancer treatment market and leverage this expansion to strengthen its presence in the European and Middle Eastern markets.
AbClon signs CAR-T cell therapy tech transfer deal with Turkey’s TCT Health
AbClon announced on Tuesday that it has signed an exclusive technology transfer agreement with TCT Health Technology, a Turkish company, for its homegrown CAR-T cell therapy, AT101. The agreement, signed on Feb. 28, will remain valid for 20 years from its effective date. Under the deal, AbClon will transfer CD19 CAR sequences, CD19 CAR-T-specific manufacturing processes and analytical methods, as well as CMC-related technologies. In return, TCT Health Technology will gain exclusive rights to develop and commercialize AT101 in the Turkish market.
Türkiye’de Yerli CD19 CAR-T Hücre Tedavisi İçin İş Birliği
TCT Sağlık, Güney Kore’nin önde gelen biyoteknoloji firmalarından AbClon ve İsveç Kraliyet Teknoloji Enstitüsü (İKTE) ile Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB), Türkiye’de yeni nesil CD19 CAR-T hücre tedavisi AT101’in klinik kullanımı ve yerli üretimi için stratejik bir iş birliği anlaşması imzaladı.
TÜSEB, CAR-T Tedavisi İçin İş Birliği Protokolü İmzaladı
CAR-T tedavisinin Türkiye’de uygulanabilir hale getirilmesi amacıyla 28 Şubat 2025 tarihinde TÜSEB ve TCT Sağlık Teknolojileri arasında iş birliği protokolü imzalandı. Bu protokol ile ülkemizde giderek artan lösemi gibi hematolojik kanserlerin tedavisinde kişiye özel yaklaşımların başarı oranını önemli ölçüde artırmak hedeflenmektedir. Türkiye’nin sağlık alanında hayata geçirdiği Üreten Sağlık Modeli çerçevesinde önemli bir adım daha atılmış oldu.
Türkiye’de CAR-T hücre tedavisi dönemi başlıyor
TCT Sağlık Teknolojileri (TCT), Güney Kore’nin önde gelen biyoteknoloji firmalarından AbClon ve İsveç Kraliyet Teknoloji Enstitüsü (İKTE) ile Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB), Türkiye’de yeni nesil CD19 CAR-T hücre tedavisi AT101’in klinik kullanımı ve yerli üretimi için stratejik bir iş birliği anlaşması imzaladı.
Kanser tedavisinde yerli teknoloji! Sağlık Bakanı Kemal Memişoğlu açıkladı: Türkiye'de yerli olarak üreteceğiz
Sağlık Bakanı Kemal Memişoğlu, Türkiye'nin, sağlık hizmetleri konusunda çok iyi bir yerde olduğunu söyleyen Bakan Memişoğlu, 'Biz aynı zamanda sağlık teknolojisi, sağlıkla ilgili bilgi üretimi konusunda da son 10 yıldır büyük çaba içindeyiz. Özellikle Sayın Cumhurbaşkanımızın politikalarında üreten sağlığı desteklemesi ile biz bunu daha da hızlandırma sürecine girdik. CAR-T Cell, kanser tedavisinde çok ileri teknoloji tedavi yöntemlerinden biri. Bunu da çok kısa zamanda Türkiye'de yerli olarak üreterek insanlarımızın hizmetine sunacağız.' ifadelerini kullandı.
Sağlık Bakanı Prof Dr. Kemal Memişoğlu 'DHA Haber Merkezi'nin konuğu oldu
Sağlık Bakanı Prof Dr. Kemal Memişoğlu 'DHA Haber Merkezi'nin konuğu oldu
Kanser için yerli tedavi çalışması
Kanser tedavisinde kullanılan (CAR-T) hücre terapisi Türkiye’de üretilecek. Sağlık Bakanı Kemal Memişoğlu, yerli immünoterapi tedavisi için çalışmaların başladığını açıkladı.
Fikirden Ürüne: Üreten Sağlık, Sağlıklı Türkiye Yüzyılı 🇹🇷
TÜSEB üzerinden sağlık alanında 'fikirden ürüne' giden bir ekosistem oluşturuyor; bu ekosistemin Millî Sağlık Teknoloji Hamlemizin taşıyıcı olmasını hedefliyoruz. Kanser tedavisinde ileri teknoloji yöntemlerden biri olan CAR-T Hücre Tedavisi'ni yerli üretim olarak vatandaşlarımızın hizmetine sunacağız.
TCT Basın Bildirisi | Türkiye’de CAR-T Hücre Tedavisi İçin Tarihi Adım
28 Şubat 2025, İstanbul – TCT Sağlık Teknolojileri (TCT), Güney Kore’nin önde gelen biyoteknoloji firmalarından AbClon ve İsveç Kraliyet Teknoloji Enstitüsü (İKTE) ile Türkiye Sağlık Enstitüleri Başkanlığı (TÜSEB), Türkiye’de yeni nesil CD19 CAR-T hücre tedavisi AT101’in klinik kullanımı ve yerli üretimi için stratejik bir iş birliği anlaşması imzaladı. Bu iş birliği kapsamında, öncelikli olarak AT101’in Türkiye’de yerel üretim altyapısı oluşturulacak ve sonrasında hematolojik kanser tedavisi için onay süreci başlatılacaktır. Anlaşma ile birlikte TCT, Türkiye’de AT101’in ticarileştirme haklarını alarak klinik denemelerin yürütülmesi ve ürünün üretim sürecinin başlatılması sorumluluğunu üstlenecektir.
CAR-T Treatment for Hematologic Cancers Expressing CD19
We are excited to announce that TCT will initiate the technology transfer process for AbClon’s AT101 protocol to Türkiye, marking a significant step forward in advanced immunotherapy. AbClon AT101 is a next-generation CAR-T therapy designed to treat blood cancers expressing CD19. Unlike conventional CAR-T therapies that target the FMC63 site, AT101 utilizes AbClon’s proprietary NEST discovery platform to develop a unique humanized antibody—offering a novel mode of action. Key advantages of AT101: Enhanced therapeutic effects compared to existing CAR-T treatments New hope for patients who do not respond to FMC63-based therapies Innovative approach using a differentiated antibody with stronger clinical impact Together, we are shaping the future of personalized cancer treatment!
A Strategic Milestone: MOU Signed Between TCT & AbClon!
We are proud to announce that TCT and AbClon have officially signed a Memorandum of Understanding (MOU), setting the foundation for a powerful collaboration in cell and gene therapies. The final agreement will be signed in Q1 of 2025. During our meetings with AbClon, we explored potential CAR-T therapy advancements, discussed innovative immunotherapy strategies, and aligned our vision to accelerate the development of next-generation cancer treatments. This agreement will focus on: ✅ Advancing CAR-T cell therapy applications ✅ Enhancing collaboration in clinical and commercial manufacturing ✅ Driving technology transfer and R&D innovation locally This partnership signifies a major step toward strengthening biotechnology capabilities in Turkey and beyond. We are excited to work together and bring groundbreaking treatments to patients worldwide!
Strategic Discussions on Cell Therapies with TÜBİTAK MAM!
We had the privilege of engaging in insightful discussions on cell therapy advancements and R&D collaborations during our visit to TÜBİTAK MAM. TCT Chairman Öztürk Oran and CEO Erkan Mankan shared key updates on cell therapy innovations and explored opportunities for potential joint projects. This meeting underscored the importance of strategic cooperation in accelerating biotechnology and advanced therapy development in Türkiye. A special thank you to TÜBİTAK President Prof. Dr. Orhan Aydın and his team for their valuable contributions and visionary support for R&D initiatives. We are very excited about the future collaborations ahead! Together, we are shaping the future of biotechnology.
🌍 Meaningful Visit by GI Cell & GI Innovation Teams to Turkey!
We had the pleasure of hosting the GI Cell and GI Innovation teams during their visit to Turkey, where they explored local infrastructures and discussed the growing importance of cell and gene therapies in drug development. This visit highlighted GI Cell's remarkable progress with their NK product, which has demonstrated exceptional success in addressing solid tumor applications through GI Smart, minimizing errors and enhancing outcomes. The teams emphasized that the journey dedicated to drug development must expand with cell and gene therapies to meet the needs of modern medicine. A big thank you to GI Cell and GI Innovation for this inspiring collaboration! Excited to see what the future holds as we work together to advance biotechnology.
Exploring Strategic Synergies with GI Cell in Next-Gen Immunotherapies
We recently visited GI Cell, a pioneering biotechnology company based in South Korea. GI Cell specializes in immunotherapy solutions, focusing on allogeneic NK (Natural Killer) cell therapies for cancer and multivalent subunit vaccines. During the visit, discussions were held on GI Cell's innovative platforms for screening and optimizing immune cell proteins, which aim to deliver safer and more effective cell therapies. This visit also included preliminary discussions for an MOU, laying the groundwork for potential collaboration between TCT and GI Cell to accelerate advancements in cell and gene therapy. With its impressive state-of-the-art facilities and recent achievements, such as completing a $68 million Series B funding round, GI Cell is set to play a crucial role in shaping the future of biotechnology. Together, we look forward to exploring opportunities that will drive impactful innovations and transformative healthcare solutions.
Taking another big step forward!
Today, as TCT, we had the pleasure of hosting the CEO and CTO of AbClon. Significant progress was made towards finalizing an MOU (Memorandum of Understanding) to strengthen our collaboration. As part of the visit, we also explored TÜBİTAK Medibiyo and Biruni University to discuss potential joint projects in cell therapy and biotechnology. This partnership with AbClon marks a critical milestone for bringing international opportunities in CAR-T cell therapy and gene therapies to Turkey. Our aim is to position our country at the forefront of biotechnology innovation and support local production initiatives. 🤝 Stay tuned for updates on our new collaborations and projects!
Inspiring visit to Koç University Hospital!
We had the privilege of visiting the Clinical Trials Unit and meeting Prof. Dr. Müjdat Zeybel. Koç University’s research capabilities are paving the way for innovation in advanced therapies. Excited for future collaborations to drive healthcare innovation in Turkey!
Advancing Cell and Gene Therapy Through Strategic Collaboration with Cytiva
During our recent visit to Cytiva's facility in Grens, Switzerland, Erkan Mankan, our CEO, led discussions on Cytiva’s critical role in supporting protocol validation, conducting feasibility studies, and fostering R&D collaborations with TCT. With their state-of-the-art GMP-ready Fast Trak laboratory and expertise in end-to-end biomanufacturing solutions, Cytiva is seen as a key partner in accelerating our shared goals. By leveraging Cytiva's innovative capabilities, TCT aims to enhance research outcomes, validate protocols, and drive impactful developments in cell and gene therapies.
Positioning Kayseri as a Regional Hub for Biotechnology and Cell Therapy
We had the honor of meeting with the Erciyes University rector and Prof. Dr. Halil Ulutabanca, who emphasized Kayseri’s potential to become the pioneer of biotechnology in Anatolia. With its well-established infrastructure and over $50 million in donations for biotechnology investments, Kayseri is positioning itself as the cellular therapy hub of the region. This ecosystem, enriched with advanced capabilities, is set to play a pivotal role in shaping the future of biotechnology in Turkey. We are excited to collaborate with Erciyes University.
Driving Biotechnology Innovation in Turkey Through Strategic Collaboration with Cytiva
We welcomed the Cytiva Global Fast Trak team and Genomic Medicine team to Turkey for discussions on transformative technology transfer projects in collaboration with TCT. As part of this initiative, we visited Biruni University's Rectorate and TÜBİTAK Medibiyo to explore potential collaborations and evaluate key hubs for cell and gene therapy innovation. These discussions are paving the way for critical developments, with goals secured through strategic 3-way NDA agreements. This collaboration will enable us to bring cutting-edge technology and expertise to Turkey, reinforcing our commitment to localizing advanced therapies and creating a robust biotechnology ecosystem.